Achondroplasia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:15OMIM:100800Q77.4
Who is this for?
Show terms as
2FDA treatments17Active trials40Specialists8Treatment centers3Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Achondroplasia is treated with 2 medications in our database, including VOXZOGO 0.4mg, VOXZOGO 0.56mg, VOXZOGO 1.2mg, AUKELSO. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by BioMarin, Alcon. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Achondroplasia treatment below.

Clinical phenotype terms— hover any for plain English:

Bowing of the legsHP:0002979Thoracolumbar kyphosisHP:0005619Parietal bossingHP:0000242Abnormal midface morphologyHP:0000309Limited elbow extensionHP:0001377Obstructive sleep apneaHP:0002870Short nasal bridgeHP:0003194Spinal canal stenosisHP:0003416Trident handHP:0004060
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Feb 2026YUVIWEL: FDA approved
FDAcompleted
Feb 2026Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia

SYSNAV

TrialRECRUITING
Feb 2026A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

BioMarin Pharmaceutical — PHASE2, PHASE3

TrialNOT YET RECRUITING
Dec 2025A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

Abbisko Therapeutics Co, Ltd — PHASE1, PHASE2

TrialNOT YET RECRUITING
Nov 2025Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

QED Therapeutics, a BridgeBio company — PHASE2

TrialRECRUITING
Jun 2025A Study in Children With Achondroplasia

Abbisko Therapeutics Co, Ltd

TrialRECRUITING
Mar 2025A Study of TYRA-300 in Children With Achondroplasia: BEACH301

Tyra Biosciences, Inc — PHASE2

TrialRECRUITING
Dec 2024A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

Ascendis Pharma A/S — PHASE2

TrialRECRUITING
Dec 2024Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study)

Kyowa Kirin Co., Ltd. — PHASE3

TrialRECRUITING
Jul 2024A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

Ascendis Pharma Growth Disorders A/S — PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Voxzogo 0.4Mg

VOSORITIDE· BioMarin Pharmaceutical Inc.Accelerated Approval

VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses.

AUKELSO

Denosumab-kyqq· AstraZeneca

* Patient Copay Amount: Not Publicly Available * Maximum Annual Benefit Limit: Not Publicly Available * Core Eligibility Restrictions: Not Publicly Available * RxBIN, PCN, and Group numbers: Not Publi

Clinical Trials

17 recruitingView all trials with filters →
Phase 32 trials
Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study)
Phase 3
Actively Recruiting
PI: Yu Sato (Kyowa Kirin Co., Ltd.) · Sites: Ōbu, Aichi-ken; Suita, Osaka +7 more · Age: 318 yrs
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
Phase 3
Active
· Sites: Oakland, California; Torrance, California +22 more · Age: 699 yrs
Phase 29 trials
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
Phase 2
Actively Recruiting
PI: Doug Warner, MD (Tyra Biosciences) · Sites: Torrance, California; Aurora, Colorado +11 more · Age: 310 yrs
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Phase 2
Actively Recruiting
PI: Medical Director, MD (Ascendis Pharma A/S) · Sites: Saint Paul, Minnesota; Houston, Texas +15 more · Age: 02 yrs
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
Phase 2
Enrolling by Invitation
PI: QED Therapeutics SVP, Clinical Development (QED Therapeutics) · Sites: Oakland, California; Aurora, Colorado +29 more · Age: 318 yrs
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
Phase 2
Active
PI: Medical Director MD (BioMarin Pharmaceutical) · Sites: Oakland, California; Torrance, California +14 more
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
Phase 2
Active
PI: Medical Director, MD (BioMarin Pharmaceutical) · Sites: Parkville, Victoria; London +1 more
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
Phase 2
Actively Recruiting
PI: Medical Director, MD (Ascendis Pharma A/S) · Sites: Montreal; Copenhagen +3 more · Age: 1217 yrs
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
Phase 2
Active
PI: Medical Director, MD (Ascendis Pharma A/S) · Sites: Copenhagen; Dublin +1 more · Age: 211 yrs
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Phase 2
Actively Recruiting
· Sites: Oakland, California; Baltimore, Maryland +11 more
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
Phase 2
Active
PI: Medical Director, MD (BioMarin Pharmaceutical) · Sites: Oakland, California; Torrance, California +7 more · Age: 799 yrs
Other5 trials
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
Active
PI: QED Therapeutics, Inc. VP, Clinical Development (QED Therapeutics) · Sites: Oakland, California; Aurora, Colorado +30 more · Age: 017 yrs
A Study in Children With Achondroplasia
Actively Recruiting
PI: Yuan Lu (12B, Building 1, No 515, Huanke Road, Pudong New A) · Sites: Beijing, Beijing Municipality; Guangzhou, Guangzhou +6 more · Age: 011 yrs
Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
Actively Recruiting
· Sites: Milan
VIrtual STudy in Achondroplasia for the US (VISTA)
Actively Recruiting
PI: Medical Director, MD (BioMarin Pharmaceutical) · Sites: Oakland, California; San Francisco, California +5 more · Age: 018 yrs
Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
Actively Recruiting
PI: Genevieve Baujat (Hopital Necker) · Sites: Paris · Age: 365 yrs

Specialists

Showing 25 of 40View all specialists →
MI
Melita Irving
Specialist
11 Achondroplasia publications
KM
Klaus Mohnike
Specialist
9 Achondroplasia publications
MB
Michael B Bober
WILMINGTON, DE
Specialist
8 Achondroplasia publications
WW
William R Wilcox
Specialist
7 Achondroplasia publications
AL
Antonio Leiva-Gea
Specialist
6 Achondroplasia publications
VC
Val&#xe9;rie Cormier-Daire
Specialist
6 Achondroplasia publications
PH
Paul Harmatz
OAKLAND, CA
Specialist
6 Achondroplasia publications
PA
Paul Arundel
Specialist
6 Achondroplasia publications
AH
Alice Huntsman-Labed
Specialist
6 Achondroplasia publications
JL
Janet M Legare
MADISON, WI
Specialist
5 Achondroplasia publications
LT
Louise Tofts
Specialist
4 Achondroplasia publications
RS
Ravi Savarirayan
Specialist
16 Achondroplasia publications
CB
Carlos A Bacino
HOUSTON, TX
Specialist
8 Achondroplasia publications
JH
Julie Hoover-Fong
BALTIMORE, MD
Specialist
10 Achondroplasia publications
LP
Lynda E Polgreen
ORANGE, CA
Specialist
5 Achondroplasia publications
YK
Yumiko Kotani
Specialist
3 Achondroplasia publications
MM
Mohamad Maghnie
Specialist
3 Achondroplasia publications
JH
Julie E Hoover-Fong
BALTIMORE, MD
Specialist
3 Achondroplasia publications
EG
Encarna Guillén-Navarro
Specialist
2 Achondroplasia publications
IL
Isabel Leiva-Gea
Specialist
2 Achondroplasia publications
WM
William Mackenzie
Specialist
2 Achondroplasia publications
JM
Josef Milerad
Specialist
2 Achondroplasia publications
NY
Natsuo Yasui
Specialist
2 Achondroplasia publications
NM
Nadia Merchant
WASHINGTON, DC
Specialist
4 Achondroplasia publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources
Voxzogo 0.4Mg(VOSORITIDE)BioMarin Pharmaceutical Inc.

Yuviwel

Ascendis Pharma Growth Disorders A/S

Unverified — confirm before calling
copay card
copay assistancePatient Assistance
Accepting applications

1 travel grant are also available for Achondroplasia patients — see Travel Grants below ↓

Travel Grants

1 grants

BridgeBio Grants and Funding

Apply ↗

Community

Open AchondroplasiaForum →

No community posts yet. Be the first to share your experience with Achondroplasia.

Start the conversation →

Latest news about Achondroplasia

1 articles
ResearchPUBMEDApr 1, 2026
Modeling rare genetic skeletal disorders with bone organoids: a narrative review.
Scientists are developing a new way to study rare bone diseases using lab-grown bone tissue called organoids. Instead of only using animal tests or simple cell
See all news about Achondroplasia

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Achondroplasia

What is Achondroplasia?

Achondroplasia is treated with 2 medications in our database, including VOXZOGO 0.4mg, VOXZOGO 0.56mg, VOXZOGO 1.2mg, AUKELSO. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by BioMarin, Alcon. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Achondroplasia treatment below.

How is Achondroplasia inherited?

Achondroplasia follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Achondroplasia typically begin?

Typical onset of Achondroplasia is neonatal. Age of onset can vary across affected individuals.

Are there clinical trials for Achondroplasia?

Yes — 17 recruiting clinical trials are currently listed for Achondroplasia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Achondroplasia?

25 specialists and care centers treating Achondroplasia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Achondroplasia?

2 FDA-approved treatments and 3 patient support programs are currently tracked on UniteRare for Achondroplasia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.